Literature DB >> 21831565

Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Sarah A Savage1, Amanda J Abraham, Hannah K Knudsen, Tanja C Rothrauff, Paul M Roman.   

Abstract

Identifying facilitators of more rapid buprenorphine adoption may increase access to this effective treatment for opioid dependence. Using a diffusion of innovations theoretical framework, we examine the extent to which programs' interorganizational institutional and resource-based linkages predict the likelihood of being an earlier adopter, later adopter, or nonadopter of buprenorphine. Data were derived from face-to-face interviews with administrators of 345 privately funded substance abuse treatment programs in 2007-2008. Results of multinomial logistic regression models show that interorganizational and resource linkages were associated with timing of adoption. Programs reporting membership in provider associations were more likely to be earlier adopters of buprenorphine. Programs that relied more on resource linkages, such as detailing activities by pharmaceutical companies and the National Institute on Drug Abuse website, were more likely to be earlier adopters of buprenorphine. These findings suggest that institutional and resource-based interorganizational linkages may expose programs to effective treatments, thereby facilitating more rapid and sustained adoption of innovative treatment techniques.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831565      PMCID: PMC3225636          DOI: 10.1016/j.jsat.2011.06.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  49 in total

1.  Staff beliefs about addiction treatment.

Authors:  R F Forman; G Bovasso; G Woody
Journal:  J Subst Abuse Treat       Date:  2001-07

2.  A discussion of the concept of technology transfer of research-based drug "abuse" prevention and treatment interventions.

Authors:  Zili Sloboda; Sam Schildhaus
Journal:  Subst Use Misuse       Date:  2002 Jun-Aug       Impact factor: 2.164

3.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

4.  A controlled trial of buprenorphine treatment for opioid dependence.

Authors:  R E Johnson; J H Jaffe; P J Fudala
Journal:  JAMA       Date:  1992-05-27       Impact factor: 56.272

5.  Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study.

Authors:  C Uehlinger; J Déglon; S Livoti; S Petitjean; D Waldvogel; D Ladewig
Journal:  Eur Addict Res       Date:  1998       Impact factor: 3.015

6.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

7.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Authors:  Traci Rieckmann; Marilyn Daley; Bret E Fuller; Cindy P Thomas; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2006-12-08

8.  Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.

Authors:  Peter D Friedmann; Lan Jiang; Jeffrey A Alexander
Journal:  J Behav Health Serv Res       Date:  2009-03-19       Impact factor: 1.505

9.  Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.

Authors:  Lori J Ducharme; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2008-11-11

Review 10.  Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.

Authors:  Bryan R Garner
Journal:  J Subst Abuse Treat       Date:  2008-11-12
View more
  9 in total

1.  Implementation of Network for the Improvement of Addiction Treatment (NIATx) Processes in Substance Use Disorder Treatment Centers.

Authors:  Dail Fields; Hannah K Knudsen; Paul M Roman
Journal:  J Behav Health Serv Res       Date:  2016-07       Impact factor: 1.505

2.  Financial factors and the implementation of medications for treating opioid use disorders.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

3.  The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2014-05       Impact factor: 2.582

4.  Use of evidence-based treatments in substance abuse treatment programs serving American Indian and Alaska Native communities.

Authors:  Douglas K Novins; Calvin D Croy; Laurie A Moore; Traci Rieckmann
Journal:  Drug Alcohol Depend       Date:  2016-02-10       Impact factor: 4.492

5.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Authors:  Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green
Journal:  Drug Alcohol Depend       Date:  2016-01-06       Impact factor: 4.492

6.  A qualitative study of the adoption of buprenorphine for opioid addiction treatment.

Authors:  Carla A Green; Dennis McCarty; Jennifer Mertens; Frances L Lynch; Anadam Hilde; Alison Firemark; Constance M Weisner; David Pating; Bradley M Anderson
Journal:  J Subst Abuse Treat       Date:  2013-10-23

7.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Authors:  Aaron D Fox; Adam Chamberlain; Nancy L Sohler; Taeko Frost; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2014-08-07

8.  Examining the sustainment of the Adolescent-Community Reinforcement Approach in community addiction treatment settings: protocol for a longitudinal mixed method study.

Authors:  Sarah B Hunter; Lynsay Ayer; Bing Han; Bryan R Garner; Susan H Godley
Journal:  Implement Sci       Date:  2014-08-13       Impact factor: 7.327

9.  Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.

Authors:  Kristina Medlinskiene; Justine Tomlinson; Iuri Marques; Sue Richardson; Katherine Stirling; Duncan Petty
Journal:  BMC Health Serv Res       Date:  2021-11-05       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.